

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name **ALISI ANNA**
Address **75, via Augusto Renzini, 00128, Rome, Italy**
Mobile Phone **393395012692**
Date of birth **[16/11/1971]**
Place of birth **ROME-ITALY**
Fiscal Code **LSANNA71S56H501W**

PROFESSIONAL ADDRESS

Liver Research Unit, Polo di Ricerca, Piano 0- Sede San Paolo
Bambino Gesù' Children Hospital - Viale San Paolo 15, 00146 Rome - Italy
Phone **+39-06-68592186**
E-mail **ANNA.ALISI@OPBG.NET**
Nationality **ITALIAN**

WORK EXPERIENCE

- Dates (from – to) March 2000 – August 2000
• Name and address of employer University of Barcellona, Barcellona, Spain.
• Type of business or sector six month at the Department Of Biology and Pathology
• Occupation or position held PhD training
- Dates (from – to) 2002 – 2004
• Name and address of employer University of L'Aquila, Italy
• Type of business or sector Scientific Research
• Occupation or position held Post-doctoral Fellow, Internal Medicine, Hepatology Unit
- Dates (from – to) 2004 – 2007
• Name and address of employer A. Cesalpino Foundation, Rome Italy
• Type of business or sector Scientific Research
• Occupation or position held Research Fellow – Viral and Molecular Oncology Unit
- Dates (from – to) 2007 – 2010
• Name and address of employer "Bambino Gesù" Children's Hospital and Research Institute
Rome, Italy
• Type of business or sector Scientific Research
• Occupation or position held Research Fellow – Liver Research Unit
- Dates (from – to) 2011 – 2012
• Name and address of employer "Bambino Gesù" Children's Hospital and Research Institute
Rome, Italy
• Type of business or sector Scientific Research
• Occupation or position held Junior Researcher – Liver Research Unit
- Dates (from – to) 2012 – to date
• Name and address of employer "Bambino Gesù" Children's Hospital and Research Institute
Rome, Italy
• Type of business or sector Scientific Research
• Occupation or position held Senior Researcher – Liver Research Unit

EDUCATION AND TRAINING

- Dates (from – to) 1996-1997
• Name and type of organization Practical course about "Science of laboratory animals", University
of Tor Vergata, Rome, Italy.

- Dates (from – to) 1991 – 1998:
- Name and type of organisation Biology degree, University of “Sapienza”, Rome, Italy.
- Title of qualification awarded BSc.

- Dates (from – to) 1999 – 2002
- Name and type of organisation Doctoral School of Cellular and Developmental Biology, University of “Sapienza”, Rome, Italy.
- Title of qualification awarded PhD.

- Dates (from – to) 2002 – 2003
- Name and type of organisation Master on Bioinformatics, University of “Sapienza”, Rome, Italy.

- Dates (from – to) 2009 – 2013
- Name and type of organisation Specialization in Clinical Pathology, University of Tor Vergata, Rome, Italy.

- Dates (from – to) 01/2014 – 01/2020
- Name and type of organisation Accreditation to supervise research as Full Professor in Applied Biology (Abilitazione Scientifica Nazionale, 1^a e 2^a Fascia) by MIUR

MOTHER TONGUE **ITALIAN**

OTHER LANGUAGES

- Reading skills **ENGLISH**
Good
- Writing skills Good
- Verbal skills Good
- Reading skills **SPANISH**
Good
- Verbal skills Good

**SOCIAL SKILLS
AND COMPETENCES**

I have a marked aptitude for team work and I am flexible. I'm able to work under pressure alone, or as a member of a team. I am resolute, independent, ready for change, to put myself to the test.
I would like to work in a multicultural atmosphere, in a dynamic and challenging environment to put my scientific skills into practice and to improve and increase them.

**TECHNICAL SKILLS
AND COMPETENCES**

Computer:
Word, Excel, Power Point, AdobePhotoshop, EndNote, BioEdit, Quantity One, ImageLab, on line bibliographic research (PubMed) and specific programs for scientific research laboratories.
Use of databases: BLAST: Basic Local Alignment Search Tool, Ensembl Genome Browser, ExPASy Proteomics Server, STRING for protein interaction Networks; etc.
Laboratory instruments
Common instruments for molecular and cellular biology, Real-Time PCR Thermal Cyclers, spectrophotometer, nanodrop, molecular imager ChemiDoc XRS System, EnVision™ Multilabel Plate Reader, ELISA reader, optical and fluorescence microscopy, centrifuges, instruments for radioactive materials, beta-counter, automatic sequencer, chemical and sterile hood.
Cell Biology
Molecular Biology and Microbiology
Biochemistry
Animal models

SCIENTIFIC ACTIVITY

A Alisi's major contributions have been in the field of regenerative processes of liver tissue in response to hormones such as thyroid hormones and growth factors and HCV-related liver diseases. In the last 5 years, the main scientific interests have been in the field of the liver cell physiology and pathogenetic mechanisms involved in several liver diseases: liver cancer, chronic hepatitis B and C infection, non-alcoholic fatty liver disease (NAFLD). Thanks to her knowledge, she moved her interest from proliferative and differentiative processes of hepatocytes to those regulating proliferation and differentiation of other cell types, including muscle and lymphocytes.

Recently, she moved her interest on the study of pathogenic mechanism leading to non-alcoholic fatty liver disease (NAFLD) and liver fibrosis.

Dr. Alisi has conducted molecular independent research during the last 5 years (2006-2011). In fact, in the last five years the PI has established a very competitive cellular and molecular laboratory optimally integrated in the clinical environment of a Hepato-Metabolic Disease Unit at the "Bambino Gesù" Children's Hospital. In this context, Dr. Alisi has constituted a Liver Research Unit investigating molecular mechanisms involved in NAFLD development and progression. The laboratory has achieved an important international reputation. In addition, bioinformatics formation of the PI has consented in these studies also an interdisciplinary approach. The Dr. Alisi has a Senior Research position with the responsibility of budget (15000 Euros/year) and staff (one PhD student and one technician) dedicated to at least 2-years project on NAFLD-related fibrogenesis and hepatocarcinogenesis and has received other Grants (see specific section)

In all projects Anna Alisi actively participated not only to design and execution of experiments, but also contributed greatly to drafting her manuscripts (as first, corresponding and last author). Her activity is documented by **167** publications peer reviewed scientific papers on impacted journals (79 "research/original articles", 58 "reviews and editorials", and 32 "letters to Editor"), and total **impact factor** is near **1000**. 6 book chapters and several abstracts (60) complete Dr. Alisi's bibliography. Current H-index: **30 (Scopus)**.

PUBLICATIONS

"Research and Original Articles"

1. **Alisi A.**, Spagnuolo S., and Leoni S. Treatment with EGF increases the length of S-phase after partial hepatectomy in rat, changing the activities of cdk. *Cell Physiol Biochem* 2003; 13: 239-248.
2. **Alisi A.**, Leoni S., Piacentani A., and Conti Devirgiliis L. Retinoic acid modulates the cell-cycle in fetal rat hepatocytes and HepG2 cells by regulating cyclin-cdk activities. *Liver Int* 2003; 23: 179-186.
3. **Alisi A.**, Giambartolomei S., Cupelli F., Merlo P., Fontemaggi G., Spaziani A., and Balsano C. Physical and functional interaction between HCV core protein and the different p73 isoforms. *Oncogene* 2003; 22: 2573-2580.
4. **Alisi A.**, Spagnuolo S., Napoletano S., Spaziani A., and Leoni S. Thyroid hormones regulate DNA-synthesis and cell-cycle proteins by activation of PKC α and p42/44 MAPK in chick embryo hepatocytes. *J Cell Physiol* 2004; 201: 259-265.
5. **Alisi A.**, Demori I., Spagnuolo S., Pierantozzi E., Fugassa E., and Leoni S. Thyroid status affects rat liver regeneration after partial hepatectomy by regulating cell cycle and apoptosis proteins. *Cell Physiol Biochem* 2005; 15: 69-76.
6. **Alisi A.**, Mele R., Spaziani A., Tavolaro S., Palescandolo E., and Balsano C. Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells. *J Cell Physiol* 2005; 205: 25-31.
7. Spaziani A.*, **Alisi A.***, Sanna D., and Balsano C. Role of p38MAPK and PKR in HCV core-dependent nuclear delocalization of cyclin B1. *J Biol Chem* 2006; 28: 10983-10989.*Co-first authors.
8. **Alisi A.**, Giannini C., Spaziani A., Anticoli A., Caini P., Zignego AL., and Balsano C. Hepatitis C virus core protein enhances B lymphocytes proliferation. *Dig liver Dis* 2007; 39, S1: S72-75.
9. **Alisi A.**, Giannini C., Spaziani A., Caini P., Zignego AL., and Balsano

- C. Involvement of PI3K in HCV-related lymphoproliferative disorders. *J Cell Physiol* 2008; 214: 396-404.
10. **Alisi A.**, Spaziani A., Anticoli S., Ghidinelli M., and Balsano C. PKR is a novel functional direct player that coordinates skeletal muscle differentiation via p38MAPK/AKT pathways. *Cell Signal* 2008; 20: 534-542.
 11. Nobili V., Manco M., Ciampalini P., **Alisi A.**, Devito R., Bugianesi E., Marcellini M., and Marchesini G. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month observational pilot study. *Clin Ther* 2008; 30: 1168-1176.
 12. Nobili V., Alkhouri N., **Alisi A.**, Ottino S., Lopez R., Manco M., and Feldstein AE. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2009; 7: 575-579.
 13. Nobili V., Reale A., **Alisi A.**, Morino G., Trenta I., Pisani M., Marcellini M., and Raucci U. Elevated serum aminotransferases in children at the emergency unit: relationship with non-alcoholic fatty liver disease. *Dig Liver Dis* 2009; 41: 749-752.
 14. Nobili V., **Alisi A.**, Vania A., Tiribelli C., Pietrobattista A., and Bedogni G. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. *BMC Med* 2009; 7: 21.
 15. **Alisi A.**, Piemonte F., Pastore A., Panera N., Passarelli C., Tozzi G., Petrini S., Pietrobattista A., Bottazzo GF., and Nobili V. Glutathionylation of p65NF- κ B correlates with proliferating/apoptotic hepatoma cells exposed to pro- and anti-oxidants. *Int J Mol Med* 2009; 24: 319-326.
 16. Nobili V., Bedogni G., **Alisi A.**, Pietrobattista A., Alterio A., Tiribelli C., and Agostoni C. A protective effect of breastfeeding on progression of nonalcoholic fatty liver disease. *Arch Dis Child* 2009; 94: 801-805.
 17. Masotti A., Vicennati P., **Alisi A.**, Marianecchi C., Rinaldi F., Carafa M., Ortaggi G. Novel Tween[®]20 derivatives enable the formation of efficient pH-sensitive drug delivery vehicles for human hepatoblastoma. *Bioorg Med Chem Lett* 2010; 20: 3021-3025.
 18. **Alisi A.**, Manco M., Devito R., Piemonte F., and Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associate with non-alcoholic steatohepatitis in children. *J Pediatr Gastroenterol Nutr* 2010; 50: 645-649.
 19. Nobili V., Alkhouri N., Bartuli A., Manco M., Lopez R., **Alisi A.**, and Feldstein AE. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. *Pediatr Res* 2010; 67: 665-670.
 20. Nobili V., Parola M., **Alisi A.**, Marra F., Piemonte F., Mombello C, Sutti S, Povero D, Maina V, Novo E, and Albano E. Oxidative stress parameters in paediatric nonalcoholic fatty liver disease. *Int J Mol Med* 2010; 26: 471-476.
 21. Valenti L., **Alisi A.**, Galmozzi E., Bartuli A., Del Menico B., Alterio A., Dongiovanni P., Fargion S., and Nobili V. The I148M PNPLA3 gene variant and severity of paediatric non-alcoholic fatty liver disease. *Hepatology* 2010; 52: 1274-1280.
 22. Nobili V., **Alisi A.**, De Vito R., Pietrobattista A., Torre G., de Ville de Goyet J., Morino G., Bedogni G., and Pinzani M. Hyaluronic acid predicts hepatic fibrosis in children with non-alcoholic fatty liver disease. *Transl Res* 2010; 156: 229-234.
 23. **Alisi A.**, Bedogni G., De Vito R., Comparcola D., Manco M, and Nobili V. Relationship between portal chronic inflammation and disease severity in pediatric nonalcoholic fatty liver disease. *Dig Liver Dis* 2011; 43: 143-146.
 24. **Alisi A.**, Da Sacco L., Bruscalupi G., Piemonte F., Panera N., De Vito R., Leoni S., Bottazzo GF., Masotti A., and Nobili V. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. *Lab Invest* 2011; 91: 283-293.
 25. Nobili V., Bedogni G., **Alisi A.**, Pietrobattista A., Risé P., Galli C., and

- Agostoni C. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomized controlled clinical trial. *Arch Dis Child* 2011; 96: 350-353.
26. **Alisi A.**, Ghidinelli M., Zerbini A, Missale G., and Balsano C. Hepatitis c virus and alcohol: same mitotic targets but different signaling pathways. *J Hepatol* 2011; 54: 956-963.
 27. Corte C.D., Carlucci A., Francalanci P., **Alisi A.**, and Nobili V. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. *Vaccine* 2011; 29: 4654-4656 (CASE REPORT).
 28. Manco M., **Alisi A.**, Fernandez Real J-M., Equitani F., De Vito R., Valenti L., and Nobili V. Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. *J Hepatol* 2011; 55: 647-653.
 29. **Alisi A.**, Bruscalupi G., Pastore A., Petrini S., Panera N., Massimi M., Tozzi G., Leoni S., Piemonte F., and Nobili V. Redox homeostasis and post-translational modifications/activity of phosphatase and tensin homolog (PTEN) in hepatocytes from rats with diet-induced hepatosteatosis. *J Nutr Biochem* 2012; 23: 169-178.
 30. **Alisi A.**, Pastore A., Ceccarelli S., Panera N., Gnani D., Bruscalupi G., Massimi M., Tozzi G., Piemonte F., and Nobili V. Emodin prevents intrahepatic fat accumulation, inflammation and redox status imbalance during diet-induced hepatosteatosis in rats. *Int J Mol Sci* 2012; 13: 2276-2289.
 31. Fintini D., Pietrobattista A., Morino G., Cafiero G., Calzolari A., Turchetta A., Brufani C., **Alisi A.**, Giordano U., and Nobili V. Energy expenditure and insulin sensitivity evaluation in obese children affected by hepatosteatosis. *Pediatr Obesity* 2012; 7: e14-17.
 32. Valenti L., Motta BM., **Alisi A.**, Sartorelli MR., Bonaiuto G., Dongiovanni P., Rametta R. Pelusi S., Fargion S., and Nobili V. LPIN1 rs13412852 polymorphism in pediatric non-alcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr* 2012; 54: 588-593.
 33. De Vito R., **Alisi A.**, Masotti A., Ceccarelli S., Panera N., Citti A., Salata M., Valenti L., Feldstein AE., and Nobili V. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. *Int J Mol Med* 2012; 13: 2276-2289.
 34. Citti A., Boldrini R., Inserra A., **Alisi A.**, Pessolano R., Mastronuzzi A., Zin A., De Sio L., Rosolen A., Locatelli F., and Fruci D. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. *Int J Oncol* 2012; 41: 117-124.
 35. **Alisi A.**, Arciello M., Petrini S., Conti B., Missale G., and Balsano C. Focal adhesion kinase (FAK) mediates the induction of pro-oncogenic and fibrogenic phenotypes in hepatitis C virus (HCV)-infected cells. *PLoS One* 2012; 7: e44147.
 36. Rossi F, Bellini G, **Alisi A**, Alterio A, Maione S, Perrone L, Locatelli F, Miraglia del Giudice E, and Nobili V. Cannabinoid Receptor *type 2* functional variant influences liver damage in children with nonalcoholic fatty liver disease. *PLoS ONE* 2012; 7: e42259.
 37. Nobili V., Carpino G., **Alisi A.**, Franchitto A., Alpini G., De Vito R., Onori P., Alvaro D., and Gaudio E. Hepatic Progenitor Cells activation, fibrosis and adipokines production in pediatric Nonalcoholic Fatty Liver Disease. *Hepatology* 2012; 56: 2142-2153.
 38. Alkhoury N., De Vito R., **Alisi A.**, Lopez R., Feldstein AE., and Nobili V. Development and Validation of a New Histological Score for Pediatric Nonalcoholic Fatty Liver Disease (NAFLD). *J Hepatol* 2012; 57: 1312-1318.
 39. Alkhoury N., Sedki E., **Alisi A.**, Lopez R., Pinzani M., feldstein AE., and Nobili V. Combined Pediatric NAFLD Fibrosis Index and Transient Elastography to Predict Clinically Significant Fibrosis in Children with Fatty Liver Disease. *Liver Int* 2013; 33: 79-85.

40. Nobili V., Siotto M., Bedogni G., Ravà L., Pietrobattista A., Panera N., **Alisi A.**, and Squitti R. Levels of serum ceruloplasmin associate with pediatric Nonalcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr* 2013; 56: 370-375.
41. **Alisi A.**, Ceccarelli S., Panera N., Prono F., Petrini S., De Stefanis C., Pezzullo M., Tozzi A., Villani A., Bedogni G., and Nobili V. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. *PLoS One* 2013, 26: e67160.
42. Feldstein AE., Alkhoury N., De Vito R., **Alisi A.**, Lopez R., and Nobili V. Serum Cytokeratin-18 Fragment Levels Are Useful Biomarkers for Nonalcoholic Steatohepatitis in Children. *Am J Gastroenterol*. 2013; Am J Gastroenterol 2013; 108: 1526-1531.
43. Nobili V., Bedogni G., Donati B, **Alisi A.**, and Valenti L. The I148M Variant of PNPLA3 Reduces the Response to Docosahexaenoic Acid in Children with Non-Alcoholic Fatty Liver Disease. *J Med Food* 2013; 16: 957-960.
44. Nobili V., **Alisi A.**, Della Corte C., Risé P., Galli C., Agostoni C., and Bedogni G. Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children. *Nutr Metab Cardiovasc Dis* 2013, 23: 1066-1070.
45. Vella S., Gnani D., Crudele A., Ceccarelli S., De Stefanis S., Gaspari S., Nobili V., Locatelli F., Marquez V.E., Rota R., and **Alisi A.** EZH2 Down-Regulation Exacerbates Lipid Accumulation and Inflammation in *in Vitro* and *in Vivo* NAFLD. *Int J Mol Sci* 2013; 14: 24154-24168.
46. Nobili V., Carpino G., **Alisi A.**, De Vito R., Franchitto A., Alpini G., Onori P., and Gaudio E. Role of docosahexaenoic Acid treatment in improving liver histology in pediatric nonalcoholic Fatty liver disease. *PLoS One* 2014; 9: e88005.
47. Nobili V., Giorgio V., Liccardo D., Bedogni G., Morino G., **Alisi A.**, and Cianfarani S. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. *Eur J Endocrinol* 2014; 170: 547-553.
48. Nobili V., Liccardo D., Bedogni G., Salvatori G., Gnani D., Bersani I., **Alisi A.**, Valenti L., and Raponi M. Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. *Genes Nutr* 2014; 9: 392.
49. Giorgio V., Miele L., Principessa L., Ferretti F., Villa MP., Negro V., Grieco A., **Alisi A.**, and Nobili V. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. *Dig Liver Dis* 2014; 46: 556-560.
50. Cianfarani S., Inzaghi E., **Alisi A.**, Germani D., Puglianiello A., and Nobili V. Insulin-Like Growth Factor-I and -II Levels Are Associated with the Progression of Nonalcoholic Fatty Liver Disease in Obese Children. *J Pediatr* 2014; 165: 92-98.
51. Walker RW., Allayee H., Inserra A., Fruhwirth R., **Alisi A.**, Devito R., Carey ME., Sinatra F., Goran ML., and Nobili V. Macrophage accumulation and fibrosis in adipose tissue is linked to liver damage and metabolic risk in obese children. *Obesity (Silver Spring)* 2014; 22: 1512-1519.
52. Nobili V., Donati B., Panera N., Vongsakulyanon A., **Alisi A.**, Dallapiccola B., and Valenti L. A 4-Polymorphisms Risk Score Predicts Steatohepatitis In Children With Non-Alcoholic Fatty Liver Disease. *J Pediatr Gastroenterol Nutr* 2014; 58: 632-636.
53. Gnocchi D., Massimi M., **Alisi A.**, Incerpi S., and Bruscalupi G. Effect of Fructose and 3,5-Diiodothyronine (3,5-T2) on Lipid Accumulation and Insulin Signalling in Non-Alcoholic Fatty Liver Disease (NAFLD)-Like Rat Primary Hepatocytes. *Horm Metab Res* 2014; 46: 333-340.
54. **Alisi A.**, Nobili V., Ceccarelli S., Panera N., De Stefanis C., De Vito R., Vitali R., Bedogni G., Balsano C., Cucchiara S., and Stronati L. Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. *Expert Rev Mol Diagn* 2014; 14: 763-771.

55. **Alisi A.**, Bedogni G., Baviera G., Giorgio V., Porro E., Paris C., Giammaria P., Reali L., Anania F., and Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2014; 39: 1276-1285.
56. Nobili V., **Alisi A.**, Grimaldi C., Liccardo D., Francalanci P., Monti L., Castellano A., and de Ville de Goyet J. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity? *Pediatr Obes* 2014; 9: e99-102.
57. Pastore A., **Alisi A.**, di Giovamberardino G., Crudele A., Ceccarelli S., Panera N., Dionisi-Vici C., and Nobili V. Plasma Levels of Homocysteine and Cysteine Increased in Pediatric NAFLD and Strongly Correlated with Severity of Liver Damage. *Int J Mol Sci*; 15: 21202-21214.
58. Dongiovanni P., Petta S., Maglio C., Fracanzani AL., Pipitone R., Mozzi E., Motta BM., Kaminska D., Rametta R., Grimaudo S., Pelusi S., Montalcini T., **Alisi A.**, Maggioni M., Kärjä V., Borén J., Käkelä P., Di Marco V., Xing C., Nobili V., Dallapiccola B., Craxi A., Pihlajamäki J., Fargion S., Sjöström L., Carlsson LM., Romeo S., and Valenti L. TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. *Hepatology* 2015; 61: 506-514.
59. Walenbergh SM., Houben T., Hendriks T., Jeurissen ML., van Gorp PJ., Vreugdenhil AC., Adriaanse MP., Buurman WA., Hofker MH., Mosca A., Lindsey PJ., **Alisi A.**, Liccardo D., Panera N., Koek GH., Nobili V., and Shiri-Sverdlov R. Plasma cathepsin d levels: a novel tool to predict pediatric hepatic inflammation. *Am J Gastroenterol* 2015; 110: 462-470.
60. Jahnel J., Zöhrer E., **Alisi A.**, Ferrari F., Ceccarelli S., De Vito R., Scharnagl H., Stojakovic T., Fauler G., Trauner M., and Nobili V. Serum Bile Acid Levels in Children with NAFLD: A Biomarker for Progression? *J Pediatr Gastroenterol Nutr.* 2015; 61: 85-90.
61. Alkhouri N., **Alisi A.**, Okwu V., Matloob A., Ferrari F., Crudele A., De Vito R., Lopez R., Feldstein AE., and Nobili V. Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. *Dig Dis Sci* 2015; 60: 2353-2359.
62. Miccheli A., Capuani G., Marini F., Tomassini A., Praticò G., Ceccarelli S., Gnani D., Baviera G., **Alisi A.**, Putignani L., and Nobili V. Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. *Int J Obes (Lond)* 2015; 39: 1118-1125.
63. Nobili V., **Alisi A.**, Cutrera R., Carpino G., De Stefanis C., D'Oria V., De Vito R., Cucchiara S., Gaudio E., Musso G. Altered gut-liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver. *Thorax* 2015; 70: 769-781.
64. Della Corte C., Mosca A., Majo F., Lucidi V., Panera N., Giglioni E., Monti L., Stronati L., **Alisi A.**, Nobili V. Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat. *Clin Endocrinol (Oxf)* 2015; 83: 656-662.
65. Ceccarelli S., Panera N., Mina M., Gnani D., De Stefanis C., Crudele A., Rychlicki C., Petrini S., Bruscalupi G., Agostinelli L., Stronati L., Cucchiara S., Musso G., Furlanello C., Svegliati-Baroni G., Nobili V., **Alisi A.** LPS-induced TNF- α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. *Oncotarget* 2015; 6: 41434-41452.
66. Verginelli F., Adesso L., Limon I., **Alisi A.**, Gueguen M., Panera N., Giorda E., Raimondi L., Ciarapica R., Campese AF., Screpanti I., Stifani S., Kitajewski J., Miele L., Rota R., Locatelli F. Activation of an endothelial Notch1-Jagged1 circuit induces VCAM1 expression, an effect amplified by interleukin-1 β . *Oncotarget* 2015; 6: 43216-43229.
67. Schiaffini R., Liccardo D., **Alisi A.**, Benevento D., Cappa M., Cianfarani S., Nobili V. Early Glucose Derangement Detected by Continuous Glucose Monitoring and Progression of Liver Fibrosis in

- Nonalcoholic Fatty Liver Disease: An Independent Predictive Factor? *Horm Res Paediatr* 2016; 85: 29-34.
68. Donati B., Motta BM., Pingitore P., Meroni M., Pietrelli A., **Alisi A.**, Petta S., Xing C., Dongiovanni P., Del Menico B., Rametta R., Mancina RM., Badiali S., Fracanzani AL., Craxi A., Fargion S., Nobili V., Romeo S., Valenti L. The rs2294918 E434K variant modulates PNPLA3 expression and liver damage. *Hepatology* 2016; 63: 787-789.
69. Mann JP., De Vito R., Mosca A., **Alisi A.**, Armstrong MJ., Raponi M., Baumann U., Nobili V. Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease. *Hepatology* 2016; 63: 745-753.
70. Panera N., Gnani D., Piermarini E., Petrini S., Bertini E., Nobili V., Pastore A., Piemonte F., **Alisi A.** High concentrations of H2O2 trigger hypertrophic cascade and phosphatase and tensin homologue (PTEN) glutathionylation in H9c2 cardiomyocytes". *Exp Mol Pathol* 2016; 100: 199-206.
71. Povero D., Panera N., Eguchi A., Johnson CD., Papouchado BG., de Araujo Horcel L., Pinatel EM., **Alisi A.**, Nobili V., Feldstein AE. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR- γ . *Cell Mol Gastroenterol Hepatol* 2015;1:646-663.
72. Carpino G., Nobili V., Renzi A., De Stefanis C., Stronati L., Franchitto A., **Alisi A.**, Onori P., De Vito R., Alpini G., Gaudio E. Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway. *PLoS One* 2016; 11: e0157246.
73. Selvakumar PK., Kabbany MN., Lopez R., Tozzi G., **Alisi A.**, Alkhoury N., Nobili V. Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. *Dig Liver Dis* 2016 Apr 29.
74. Del Chierico F., Nobili V., Vernocchi P., Russo A., De Stefanis C., Gnani D, Furlanello C., Zandonà A., Paci P., Capuani G-, Dallapiccola B, Miccheli A., **Alisi A.**, Putignani L. Gut microbiota profiling of pediatric NAFLD and obese patients unveiled by an integrated meta-omics based approach. *Hepatology* 2017; 65: 451-464.
75. Manco M., Mosca A., De Peppo F., Caccamo R., Cutrera R., Giordano U., De Stefanis C., **Alisi A.**, Baumann U., Silecchia G., and Nobili V. The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis. *J Pediatr* 2017; 180: 31-37.
76. Della Corte C., Carpino G., De Vito R., De Stefanis C., **Alisi A.**, Cianfarani S., Overi D., Mosca A., Stronati L., Cucchiara S., Raponi M., Gaudio E., Byrne CD., Nobili V. Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. *PLoS One* 2016; 11: e0168216.
77. Mosca A., Nobili V., De Vito R., Crudele A., Scorletti E., Villani A., **Alisi A.**, Byrne CD. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. *J Hepatol* 2017; 66: 1031-1036.
78. Gnani D., Romito I., Artuso S., Chierici M., De Stefanis C., Panera N., Crudele A., Ceccarelli S., Carcarino E., D'Oria V., Porru M., Giorda E., Ferrari K., Miele L., Villa E., Balsano C., Pasini D., Furlanello C., Locatelli F., Nobili V., Rota R., Leonetti C., **Alisi A.** Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. *Cell Death Differ* 2017; 24: 889-902.

“Reviews and Editorials”

79. Balsano C., and **Alisi A.** HCV-related transformation and new therapeutic strategies: an update. *Curr Cancer Ther Rev* 2006; 2: 41-56.

80. Balsano C., and **Alisi A.** Hepatitis C virus (HCV): an RNA virus with a pro-oncogenic potential. *Dig liver Dis* 2007; 39, S1: S46-51.
81. **Alisi A.**, and Balsano C. Enhancing the efficacy of hepatocellular carcinoma chemotherapeutics with natural anticancer agents. *Nutr Rev* 2007; 65(12 Pt 1): 550-553.
82. Balsano C., and **Alisi A.** Viral hepatitis B: established and emerging therapies. *Curr Med Chem* 2008; 15: 930-939.
83. Nobili V., **Alisi A.**, Panera N., and Agostoni C. Low birth weight and catch-up-growth associated with metabolic syndrome: a ten year systematic review. *Pediatr Endocrinol Rev* 2008; 6: 241-247.
84. **Alisi A.**, Manco M., Panera N., and Nobili V. Association between type two diabetes and non-alcoholic fatty liver disease in youth. *Ann Hepatol* 2009; 8: Supplement 1: S44-S50.
85. Balsano C., **Alisi A.**, and Nobili V. Liver fibrosis and therapeutic strategies: the goal for improving metabolism. *Curr Drug Targets* 2009; 10: 505-512.
86. Balsano C., and **Alisi A.** Antioxidant effects of natural bioactive compounds. *Curr Pharm Design* 2009; 15: 3063-3073.
87. **Alisi A.**, Manco M., Vania A., and Nobili V. Pediatric nonalcoholic fatty liver disease in 2009. *J Pediatrics* 2009; 155: 469-474.
88. Nobili V., **Alisi A.**, Pietrobattista A., Amendola S., Somma R., Gennari F., and de Ville de Goyet J. Psychosocial condition after liver transplantation in children: review of literature from 2006 to 2008. *Transplant Proc* 2009; 41: 3779-3783.
89. Nobili V., **Alisi A.**, and Raponi M. Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. *World J Gastroenterol* 2009; 15: 6017-6022.
90. **Alisi A.**, Comparcola D., and Nobili V. Treatment of chronic hepatitis C in children: is it necessary and, if so, in whom? *J Hepatol* 2010; 52: 472-474.
91. **Alisi A.**, Locatelli M., and Nobili V. Non-alcoholic fatty liver disease (NAFLD) in children. *Curr Opin Clin Nutr Met Care* 2010; 13: 397-402.
92. Masotti A., Da Sacco L., Bottazzo GF., and **Alisi A.** Microarray technology: a promising tool in the field of nutrigenomics discoveries. *Crit Rev Food Sci* 2010; 50: 693-698.
93. **Alisi A.**, De Vito R., Monti L., and Nobili V. Liver fibrosis in paediatric liver diseases. *Best Pract Res Clin Gastroenterol* 2011; 25: 259-268.
94. Nobili V., Della Corte C., Monti L., **Alisi A.**, and Feldstein A. The use of ultrasound in clinical setting for children affected by NAFLD: is it safe and accurate? *Ital J Pediatr* 2011; 37: 36.
95. Della Corte C., **Alisi A.**, Iorio R., Alterio A., and Nobili V. Expert opinion on current therapies for nonalcoholic fatty liver disease. *Expert Opin Pharmacother* 2011; 12: 1901-1911.
96. **Alisi A.**, and Nobili V. Non-alcoholic fatty liver disease in children now: Lifestyle changes and pharmacologic treatments. *Nutrition* 2012; 28: 722-726.
97. **Alisi A.**, and Nobili V. Nonalcoholic fatty liver disease: Targeted therapy in children-what is the right way? *Nat Rev Gastroenterol Hepatol* 2011; 8: 425-426.
98. **Alisi A.**, Bartuli A., Salata M., Villani A., and Nobili V. Recent advances in biomarkers for non-invasive diagnosis of NASH: the role of lipid analysis/profiling. *Clinical Lipidol* 2011; 6: 427-436.
99. Nobili V., Monti L., **Alisi A.**, Lo Zupone C., Pietrobattista A., and Tomà P. The use of transient elastography for the assessment of fibrosis in paediatric liver diseases. *Pediatr Radiol* 2011; 41: 1232-1238.
100. **Alisi A.**, Carsetti R., and Nobili V. Pathogen or damaged associated molecular patterns during non-alcoholic fatty liver disease development. *Hepatology* 2011; 54: 1500-1502.
101. **Alisi A.**, Panera N., Agostoni C., and Nobili V. Intrauterine Growth Retardation and Non-Alcoholic Fatty Liver Disease in Children. *Int J Endocrinol* 2011; 2011: 269853.
102. Masotti A., and **Alisi A.** Integrated bioinformatics analysis of

- microRNA expression profiles for an in-depth understanding of pathogenic mechanisms in non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2012; 27: 187-188.
103. **Alisi A.**, Cianfarani S., Manco M., Agostoni C., and Nobili V. Nonalcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. *Ann Med* 2012; 44: 29-40.
 104. **Alisi A.**, Feldstein AE., Villani A., Raponi M., and Nobili V. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. *Nat Rev Gastroenterol Hepatol* 2012; 9:152-161.
 105. Valenti L., **Alisi A.**, and Nobili V. Unraveling the genetics of fatty liver in obese children: Additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. *Hepatology* 2012; 55:1311.
 106. **Alisi A.**, and Nobili V. Sensitive non-invasive circulating markers in paediatric non-alcoholic fatty liver disease. *Ped Obesity* 2012; 7: 89-91.
 107. **Alisi A.**, and Nobili V. Nonalcoholic fatty liver disease in children now: lifestyle changes and pharmacological treatments. *Nutrition* 2012; 28:722-726.
 108. **Alisi A.**, and Baffet G. Self-renewal of tumor-initiating cells: what's new about hepatocellular carcinoma? *Gastroenterology* 2012; 142: 1414-1416.
 109. Della Corte C., **Alisi A.**, Alessia S., De Vito R., Vania A., and Nobili V. Non-Alcoholic Fatty Liver in Children and Adolescents: An Overview. *J Adolesc Health* 2012; 51: 305-312.
 110. **Alisi A.**, and Nobili V. Transient elastography and serum biomarkers: two-step screening methods before liver biopsy. *Expert Opin Med Diagn* 2012; 6: 377-380.
 111. Tomaselli S., Panera N., Gallo A., and **Alisi A.** Circulating microRNAs profiling as biomarkers of dysmetabolism. *Biomark Med* 2012; 6: 729-742.
 112. **Alisi A.**, Ceccarelli S, Panera N, Nobili V. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. *Front Cell Infect Microbiol* 2012; 2: 132.
 113. Nobili V., Svegliati-Baroni G., **Alisi A.**, Miele L., Valenti L., and Vajro P. A 360-degree overview of paediatric NAFLD: recent insights. *J Hepatol* 2013; 58: 1218-1229.
 114. Frasinariu O.E., Ceccarelli S., **Alisi A.**, Moraru E., and Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. *Digest liver Dis* 2013; 45: 543-551.
 115. **Alisi A.**, Ceccarelli S., and Nobili V. Transient elastography and serum biomarkers: two-step screening methods for liver fibrosis in non-alcoholic fatty liver disease before liver biopsy. *Expert Opin Med Diagn* 2012;6: 377-380.
 116. **Alisi A.**, Carpino G., and Nobili V. Pediatric NAFLD. *Curr Opin Gastroenterol* 2013; 29: 279-284.
 117. Putignani L., Massa O., and **Alisi A.** Engineered *Escherichia coli* as new source of flavonoids and terpenoids. *Food Res Int* 2013; in press. *Food Res Int* 2013; 54: 1084-1095.
 118. Liccardo D., **Alisi A.**, Porta G., and Nobili V. Is there any link between dietary pattern and development of nonalcoholic fatty liver disease in adolescence? An expert review. *Expert Rev Gastroenterol Hepatol* 2013; 7: 601-604.
 119. Tomaselli S., Bonamassa B., **Alisi A.**, Nobili V., Locatelli F., and Gallo A. ADAR enzyme and miRNA story: a base that can make the difference. *Int J Mol Sci* 2013; 4: 22796-22816.
 120. **Alisi A.**, Cho WC., Locatelli F., Fruci D. Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. *Int J Mol Sci* 2013; 14: 24706-24725.
 121. Del Chierico F., Gnani D., Vernocchi P., Petrucca A., **Alisi A.**, Dallapiccola B., Nobili V., and Lorenza P. Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools

- and applications. *Int J Mol Sci* 2014 7; 15: 684-711.
122. **Alisi A.**, Panera N., and Nobili V. FGF21 holds promise for treating obesity-related insulin resistance and hepatosteatosis. *Endocrinology* 2014; 155: 343-346.
 123. Alterio A., **Alisi A.**, Liccardo D., and Nobili V. Non-alcoholic fatty liver and metabolic syndrome in children: a vicious circle. *Horm Res Ped* 2014; 82: 283-289.
 124. Panera N., Gnani D., Crudele A., Ceccarelli S., Nobili V., and **Alisi A.** MicroRNAs as controller systems and controllers in non-alcoholic fatty liver disease. *World J Gastroenterol* 2014; 20: 15079-15086.
 125. Della Corte C., Liccardo D., Ferrari F., **Alisi A.**, and Nobili V. Current pharmacotherapy for treating pediatric non-alcoholic fatty liver disease. *Exp Opin Pharmacother* 2014; 15: 2501-2511.
 126. Ceccarelli S., Nobili V., and **Alisi A.** Toll-like receptor-mediated signaling cascade as regulator of the inflammation network during alcoholic liver disease. *World J Gastroenterol* 2014; 20: 16443-16451.
 127. Nobili V., Alkhoury N., **Alisi A.**, Della Corte C., Fitzpatrick E., Raponi M., Dhawan A. Nonalcoholic fatty liver disease: a challenge for pediatricians. *JAMA Pediatr* 2015; 169: 170-176.
 128. Paschetta E., Belci P., **Alisi A.**, Liccardo D., Cutrera R., Musso G., Nobili V. OSAS-Related Inflammatory Mechanisms of Liver Injury in Nonalcoholic Fatty Liver Disease. *Mediators Inflamm* 2015; 2015: 815721.
 129. Nobili V., **Alisi A.**, Musso G., Scorletti E., Calder PC., Byrne CD. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. *Crit Rev Clin Lab Sci* 2015 Oct 14: 1-15.
 130. Nobili V., **Alisi A.**, Newton KP., Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2016;150: 1798-1810.
 131. Corte CD., Mosca A., Vania A., Alterio A., **Alisi A.**, and Nobili V. Pediatric liver diseases: current challenges and future perspectives. *Expert Rev Gastroenterol Hepatol* 2016; 10: 255-65.
 132. Panera N., Della Corte C., Crudele A., Stronati L, Nobili V., **Alisi A.** Recent advances on adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. *Exp Rev Gastroenterol Hepatol* 2016; 10: 393-403
 133. Putignani L., **Alisi A.**, and Nobili V. Pediatric NAFLD: the Future role of Patient-Tailored Probiotics Therapy. *J Pediatr Gastroenterol Nutr* 2016; 63 Suppl 1:S6-8.
 134. Women in Hepatology Group; Italian Association for the Study of the Liver (AISF). AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). *Dig Liver Dis* 2016; 48: 860-868.
 135. Panera N., Crudele A., Romito I., Gnani D., and **Alisi A.** Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. *Int J Mol Sci* 2017; 18: pii: E99.
 136. **Alisi A.**, Carpino G., Oliveira FL., Panera N., Nobili V., and Gaudio E.. The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. *Mediators Inflamm* 2017; 2017: 8162421.

“Book Chapters”

- **Alisi A.**, and Balsano C. Chapter 5: Redox status alterations and metabolic disorders. pp. 61-78.
- Balsano C., and **Alisi A.** Chapter 7: Role of oxidative stress in the pathogenesis of cancer. pp. 103-122.
- Balsano C., **Alisi A.**, and Bocedi A. Chapter 8: Conclusions. pp. 123-125.

Published by Transworld Research Network; Oxidative Stress,

Dysregulation of Cell Homeostasis and Induction of Cell Transformation; Editor: C. Balsano; 2009.

Alisi A., Manco M., Ciampalini P., Marcellini M., and Nobili V. Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Insulin Resistance: Pathogenetic and Therapeutic Implications. **NOVA PUBLISHER BOOKS; Insulin Resistance: New Research;** Editor: E. B. Yao; 2009, pp. 343-360.

Alisi A., Manco M., Devito R., and Nobili V. Fatty Liver Disease. Springer Science+Business Media, **Contemporary endocrinology: Pediatric Obesity: Etiology, Pathogenesis and Treatment.** Editor: M. Freemerk; 2010, Chapter 15, p201-222. DOI 10.1007/978-1-60327-874-4_15

Nobili V., Alisi A., Manco M. Role of Fatty Liver Disease in Childhood Obesity. by Elsevier Inc. **Global Perspectives on Childhood Obesity.** Editor: D. Bagchi; 2010, Chapter 21, p221-230.

“Other contributions”

Graphical contribution to the manuscript (see acknowledgements): A novel mutation in the DLG3 gene encoding the synapse-associated protein 102 (SAP102) causes non-syndromic mental retardation. Zanni G, van Esch H, Bensalem A, Saillour Y, Poirier K, Castelneau L, Ropers HH, de Brouwer AP, Laumonnier F, Fryns JP, Chelly J. *Neurogenetics* 2010; 11: 251-525.

Graphical contribution to the manuscript (see acknowledgements): Gut Microbiota, Lipopolysaccharides, and Innate Immunity in the Pathogenesis of Obesity and Cardiovascular Risk. Manco M, Putignani L, Bottazzo GF. *Endocr Rev* 2010;31: 817-844.

PRIZES AND HAWARDS

- EASL (European Association for the Study of the liver) Young Investigators Bursary 2003; Meeting EASL 2003 (Geneva, Switzerland).
- EASL (European Association for the Study of the liver) Young Investigators Bursary 2005; Meeting EASL 2005 (Paris, France).
- Prize ALCRI (Associazione Italiana per la lotta alle crioglobulinemie)-AISF (Associazione Italiana per lo Studio del Fegato) 2005 (Firenze, Italy).
- ESPGHAN (European Society for Paediatric Gastroenterology, Hepatology and Nutrition) Young Investigators Awards 2010 (Istanbul, Turkey).
- Official member of the International Group “Women in Hepatology”

TEACHING ACTIVITIES

- Specific lessons and seminars for PhD courses in Cellular Physiology, Cellular and Developmental Biology at the University of Rome “La Sapienza” (2003, 2005, 2008), Gastroenterology and Cardiology at the University of L’Aquila (2004).
- Specific lessons in Cell Biology, NAFLD pathogenesis, and imaging analysis in liver research for Web-Valley School 2013.
- Tutors for Thesis and PhD in Biological Science, Cellular and Developmental Biology (2005-2013).
“Tutoring”
 - Tutoring of 3 PhD thesis, Tutoring of 2 Master Thesis;
Tutoring of several graduate.

GRANTS

As PI:

- Grant from From Italian Ministry of Health 2013 and 2014 (Fondi di Ricerca Corrente and 5x1000) (PI). Title: Molecular Pathogenesis of NAFLD.
- Grant AIRC (Associazione Italiana Ricerca sul Cancro): MFAG 12936 (2013-2016). Title Role of focal adhesion kinase as master regulator of fibrogenesis and metastasis in hepatocellular carcinoma (PI).
- Ricerca Corrente (Ministry of Health) 2014-2017.

- Project by Fondazione Bambino Gesù on HCC therapy (2017-2018).

INVITED LECTURES AND TALKS

INVITED SPEAKER AT:

- “Women in Hepatology” *Modena 2012* - ECM
- “Women in Hepatology” *Modena 2013* - ECM
- “Scientific Writing” *OPBG, Rome 2013* - ECM
- “Strategie per far finanziare un progetto” *OPBG, Rome 2014* - ECM
- “Genetica, Obesità e Steatosi Epatica” *Bari 2014* - ECM
- “Women in Hepatology” *Modena 2014* - ECM
- “Women in Hepatology” *Modena 2015* - ECM
- “Master Class in Pediatria”, *Ischia 2015* - ECM
- “Microbioteat - interazione cibo-ospite microbiota e salute e crescita infantile”, *Roma, 2015* - ECM

I authorize the use of my personal data according to the D.Lgs 196/2003

“Ai sensi e per effetto del D.Lgs. n. 196/2003 ‘Codice in materia di protezione dei dati personali e sensibili’, autorizzo al trattamento dei dati e delle informazioni contenute nel curriculum vitae ai fini del procedimento ECM, consapevole che il CV verrà incluso nell’allegato all’atto della validazione della richiesta di accreditamento, e che sarà visibile nella Banca Dati del sito ECM, accessibile a tutti gli utenti e tramite INTERNET (motori di ricerca). Autorizzo altresì il trattamento ai fini della trasmissione (successiva allo svolgimento dell’evento formativo) alla Commissione Nazionale per la Formazione Continua”

Rome 10/11/2017

Anna Alisi

